A Study to Assess Adverse Events, Change in Disease Activity, and How Intravenous and Subcutaneous Risankizumab Moves Through the Body of Pediatric Participants With Moderately to Severely Active Crohn's Disease
for Crohn's Disease
Drug: Risankizumab
Sites in Indianapolis +10 more locations
Sponsor: AbbVie
Sex: All·Age: 2 - 17
Code: NCT05995353·Phase 3·Recruiting·Listed Aug 2023